Thyroid hormone oral dosage forms and methods of using the same
Novel thyroid hormone oral dosage forms and methods of making and using the thyroid hormone oral dosage forms are disclosed.
1. A packaged immediate release oral solid dosage form product comprising:
an immediate release oral solid dosage form including:
about 0.1% to 1% levothyroxine salt, in weight percent based on total weight of the immediate release oral solid dosage form;
a hydrophilic polymer selected from the group consisting of hydroxypropyl methylcellulose (HPMC), hydroxypropylcellulose (HPC), polyethylene oxide (PEO), methyl cellulose, gum arabic, polyvinyl alcohol, tragacanth, hydroxyethylcellulose (HEC), xanthan gum, carrageenan, ceratonia , guar gum, pectin, and cross-linked high amylose starch; and
an antioxidant selected from the group consisting of butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ethylenediaminetetraacetic acid (EDTA), sodium metabisulfite, ascorbic acid, citric acid, ascorbyl palmitate, sodium isoascorbate, dihydroguaretic acid, potassium sorbate, sodium bisulfate, sorbic acid, potassium ascorbate, vitamin E, 4-chloro-2,6-diteriarybutylphenol, alphatocopherol, propylgallate, and combinations of two or more thereof;
a container closure system comprising a container of about 55 cm 3 to about 125 cm 3 and a sealing closure;
provided that about 90 to about 100 of the oral solid dosage forms and at least about 6 grams of desiccant are enclosed in the container sealed with the sealing closure; and
provided that each oral solid dosage form retains at least 95% of an initial amount of the levothyroxine salt when stored at a temperature ranging from 23° C. to 27° C. and a relative humidity ranging from 55% to 65% for six months.
2. The packaged immediate release oral solid dosage form product of claim 1 , wherein the oral solid dosage form further comprises a lubricant.
3. The packaged immediate release oral solid dosage form product of claim 2 , wherein the lubricant is magnesium stearate.
4. The packaged immediate release oral solid dosage form product of claim 1 , wherein all hydrophilic polymer in the oral solid dosage form consists of HPMC.
5. The packaged immediate release oral solid dosage form product of claim 4 , wherein the oral solid dosage form further comprises a lubricant.
6. The packaged immediate release oral solid dosage form product of claim 5 , wherein the lubricant is magnesium stearate.
7. The packaged immediate release oral solid dosage form product of claim 1 , wherein all hydrophilic polymer in the oral solid dosage form consists of HPC.
8. The packaged immediate release oral solid dosage form product of claim 7 , wherein the oral solid dosage form further comprises a lubricant.
9. The packaged immediate release oral solid dosage form product of claim 8 , wherein the lubricant is magnesium stearate.
10. The packaged immediate release oral solid dosage form product of claim 1 , wherein all hydrophilic polymer in the oral solid dosage form consists of PEO.
11. The packaged immediate release oral solid dosage form product of claim 10 , wherein the oral solid dosage form further comprises a lubricant.
12. The packaged immediate release oral solid dosage form product of claim 11 , wherein the lubricant is magnesium stearate.
13. The packaged immediate release oral solid dosage form product of claim 1 , wherein the oral solid dosage form comprises about 0.1% to about 8% HPMC, in weight percent based on total weight of the oral solid dosage form.
14. The packaged immediate release oral solid dosage form product of claim 1 , wherein the oral solid dosage form comprises about 0.1% to about 8% HPC, in weight percent based on total weight of the oral solid dosage form.
15. The packaged immediate release oral solid dosage form product of claim 1 , wherein the oral solid dosage form comprises about 0.1% to about 8% PEO, in weight percent based on total weight of the oral solid dosage form.
16. An A packaged immediate release oral solid dosage form product comprising:
an immediate release oral solid dosage form including:
about 0.1% to 1% levothyroxine salt, in weight percent based on total weight of the immediate release oral solid dosage form;
a hydrophilic polymer selected from the group consisting of hydroxypropyl methylcellulose (HPMC), hydroxypropylcellulose (HPC), polyethylene oxide (PEO), methyl cellulose, gum arabic, polyvinyl alcohol, tragacanth, hydroxyethylcellulose (HEC), xanthan gum, carrageenan, ceratonia , guar gum, pectin, and cross-linked high amylose starch;
butylated hydroxyanisole; and
at least one lubricant;
a container closure system comprising a container of about 55 cm 3 to about 125 cm 3 and a sealing closure;
provided that about 90 to about 100 of the oral solid dosage forms and at least about 6 grams of desiccant are enclosed in the container sealed with the sealing closure; and
provided that each oral solid dosage form enclosed in the container retains at least 95% of an initial amount of the levothyroxine salt when stored at a temperature ranging from 23° C. to 27° C. and a relative humidity ranging from 55% to 65% for six months.
17. The packaged immediate release oral solid dosage form product of claim 16 , wherein the oral solid dosage form comprises about 0.01% to about 5% butylated hydroxyanisole, in weight percent based on total weight of the oral solid dosage form.
18. The packaged immediate release oral solid dosage form product of claim 16 , wherein the oral solid dosage form further comprises magnesium stearate.
19. A packaged immediate release oral solid dosage form product comprising:
an immediate release oral solid dosage form including:
about 0.1% to 1% levothyroxine salt, in weight percent based on total weight of the immediate release oral solid dosage form;
a hydrophilic polymer selected from the group consisting of hydroxypropyl methylcellulose (HPMC), hydroxypropylcellulose (HPC), polyethylene oxide (PEO), methyl cellulose, gum arabic, polyvinyl alcohol, tragacanth, hydroxyethylcellulose (HEC), xanthan gum, carrageenan, ceratonia , guar gum, pectin, and cross-linked high amylose starch; and
an antioxidant selected from the group consisting of butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ethylenediaminetetraacetic acid (EDTA), sodium metabisulfite, ascorbic acid, citric acid, ascorbyl palmitate, sodium isoascorbate, dihydroguaretic acid, potassium sorbate, sodium bisulfate, sorbic acid, potassium ascorbate, vitamin E, 4-chloro-2,6-diteriarybutylphenol, alphatocopherol, propylgallate, and combinations of two or more thereof;
a container closure system comprising a container of about 225 cm 3 to about 360 cm 3 and a sealing closure;
provided that about 900 to about 1000 of the oral solid dosage forms and at least about 16 grams of desiccant are enclosed in the container sealed with the sealing closure; and
provided that each oral solid dosage form enclosed in the container retains at least 95% of an initial amount of the levothyroxine salt when stored at a temperature ranging from 23° C. to 27° C. and a relative humidity ranging from 55% to 65% for six months.